Announcement

Social Media

Meeting Flyer & Brochure

Scientific Program

Will be Announced on a Later Date
  • Origin of Antiphospholipid Antibodies
  • Genetics of Antiphospholipid Antibodies/Syndrome
  • Mechanism(s) of Antiphospholipid Antibody-mediated Thrombosis
  • Mechanism(s) of Antiphospholipid Antibody-mediated Pregnancy Morbidity
  • Target Cells and Receptors that Interact with Antiphospholipid Antibodies
  • Definition, Epidemiology, and Natural History of Antiphospholipid Syndrome
  • Impact of Antiphospholipid Syndrome in General Population with Thrombosis and Pregnancy Morbidity
  • Association with Antiphospholipid Syndrome and Other Systemic Autoimmune Diseases (Systemic Lupus Erythematosis, Rheumatoid Arthritis)
  • Microangiopathic and Catastrophic Antiphospholipid Syndrome
  • Impact of Pediatric APS in Children with Thrombosis
  • Clinical and Prognostic Significance of “Criteria” and “Non-criteria” Antiphospholipid Antibody Tests
  • Strengths and Limitations of the Current Classification Criteria
  • Disease Measurement Criteria in Antiphospholipid Syndrome
  • Most Recent Strategies in the Treatment of Thrombosis in General Population
  • Current Treatment strategies for Non-obstetric Antiphospholipid Syndrome
  • Current Treatment strategies for Obstetric Antiphospholipid Syndrome
  • Antiphospholipid Syndrome Treatment Trends (Ongoing and Planned Interventional Studies with New Generation Oral Anticoagulants, B-cell inhibition, Complement Inhibition, Hydroxychloroquine, Statins, Peptide Therapy, and others)
  • Antiphospholipid Antibodies, Antiphospholipid Syndrome (APS), and Obstetric APS for Patients

Selected Sessions

The Scientific Planning Committee will chair sessions on their areas of expertise. The meeting will produce a state-of-the-art APS book, entitled “APS – Current Research Highlights and Clinical Insights” to be published in early 2017. Selected sessions include:
HISTORY OF ANTIPHOSPHOLIPID SYNDROME
Overview of the Last 31 years and 15 International Congresses on Antiphospholipid Antibodies
Chairs: Michael D Lockshin, Nigel E. Harris

BASIC SCIENCE ASPECTS OF ANTIPHOSPHOLIPID SYNDROME
What are the Natural Proteins Involved in Antiphospholipid Syndrome?
Chairs: Philip G. de Groot, Steve Krilis

What is the Origin of Antiphospholipid Antibodies?
Chairs: Rohan Willis, Joyce Rauch

What is the Genetics of Antiphospholipid Antibodies/Syndrome?
Chair: Thomas Ortel

What is the Mechanism(s) of Antiphospholipid Antibody-mediated Thrombosis?
Chairs: Rohan Willis, Philip G. de Groot, Steve Krilis

What is the Mechanism(s) of Antiphospholipid Antibody-mediated Pregnancy Morbidity?
Chairs: Vikki Abrahams, Jane Salmon

CLINICAL & DIAGNOSTIC ASPECTS OF ANTIPHOSPHOLIPID SYNDROME
What are the Definition, Epidemiology, and Natural History of Antiphospholipid Syndrome?
Chairs: Stephane Zuily, Roger A. Levy, Denis Wahl, Michael Lockshin

What are Microangiopathic and Catastrophic Antiphospholipid Syndrome?
Chairs: Gerard Espinosa, Ricard Cervera

What are the Clinical and Prognostic Significance of “Criteria” and “Non-criteria” Antiphospholipid Antibody Tests?
Chair: Laura Bertolaccini

What are the Disease and Risk Measurement Criteria in Antiphospholipid Syndrome?
Chair: Mary-Carmen Amigo
THERAPEUTIC ASPECTS OF ANTIPHOSPHOLIPID SYNDROME
Prevention & Treatment of Thrombotic Antiphospholipid Syndrome
Chairs: Guillermo Ruiz-Irastorza, Mark Crowther

Prevention & Treatment of Obstetric Antiphospholipid Syndrome
Chairs: Ware Branch, Guilherme de Jesus

Treatment of Non-Criteria Manifestations and/or Difficult Clinical Situations in Antiphospholipid Syndrome
Chair: Danieli Andrade, Renata Rosa

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Update
Chair: Doruk Erkan

15th INTERNATIONAL CONGRESS ON ANTIPHOSPHOLIPID ANTIBODIES TASK FORCE REPORTS
Task Force Report on Antiphospholipid Syndrome Diagnostic and Classification Criteria
Chairs: Doruk Erkan, Medha Barbhaiya, Karen Costenbader

Task Force Report on Pediatric Antiphospholipid Syndrome
Chairs: Barry Myones, Tadej Avcin

Task Force on Catastrophic Antiphospholipid Syndrome
Chairs: Ricard Cervera, Gerard Espinosa

Task Force Report on Antiphospholipid Syndrome Treatment Trends (Ongoing and Planned Interventional Studies)
Chairs: Danieli Andrade, Maria G. Tektonidou

ANTIPHOSPHOLIPID SYNDROME FOR PATIENTS
What Should Patients Know About Antiphospholipid Antibodies and Antiphospholipid Syndrome?
Chairs: Doruk Erkan, Michael Lockshin

What Should Patients Know About Obstetric Antiphospholipid Syndrome?
Chairs: Lisa Sammaritano, Roger A. Levy